Rule 16, Drugs (Prices Control) Order, 2013: Revision of ceiling price of scheduled formulations
Drugs (Prices Control) Order, 2013 - Rule 16
Text of rule 16
Revision of ceiling price of scheduled formulations
16. Revision of ceiling price of scheduled formulations.– (1)
The Government shall revise the ceiling prices of scheduled
formulations as per the annual wholesale price index (WPI) for
15. Fixation of retail price of a new drug for existing
manufacturers of scheduled formulations.— (1) The Government
shall form a Standing Committee of such Experts, as it may deem fit,
within sixty days of notification of this order with a view to
recommend the retail prices of new drugs on the principles of
“Pharmacoeconomics”.
(2) Where an existing manufacturer of a drug with dosages and
strengths as specified in National List of Essential Medicines launches
a new drug, such existing manufacturers shall apply for prior price
approval of such new drug from the Government in Form-I specified
under Schedule-II of this Order.
(3) On receipt of the application under sub-paragraph (2), in the
event of the new drug available in domestic market, the Government
shall fix the retail price of the new drug in accordance with the
provision of sub-paragraph(1) of paragraph 5 and in the event of the
new drug not available in domestic market, the Government shall
forward the same to the Standing Committee of Experts who shall
examine the application on the principles of “Pharmacoeconomics”
and make recommendations of retail price of the new drug to the
Government within thirty days of the receipt of application.
(4) The Government shall, on receipt of recommendation under sub-
paragraph (3), within thirty days, fix the retail price of such new
drug and such price shall be applicable to such applicant of such new
drug.
(5) Where existing manufacturer of scheduled formulation fails to
apply for prior approval of the price of the new drug in Form-I, such
manufacturer shall be liable to deposit the overcharged amount over
and above such price fixed and notified by the Government, if any,
along with interest thereon from the date of launch of the new drug,
in addition to the penalty.
(6) No existing manufacturer of a scheduled formulation shall sell
such a new drug at a price higher than the retail price (plus local
taxes as applicable) fixed by the Government for such new drug and
in case such a manufacturer is found to sell such a new drug at a
price higher than the retail price (plus local taxes as applicable) fixed
by the Government, such manufacturer of the new drug shall be
liable to deposit the overcharged amount along with interest from
the date of overcharge, in addition to the penalty.
16. Revision of ceiling price of scheduled formulations.— (1)
The Government shall revise the ceiling prices of scheduled
formulations as per the annual wholesale price index (WPI) for
preceding calendar year on or before 1st April of every year and
notify the same on the 1st day of April every year.
(2) The manufacturers may increase the maximum retail price (MRP)
of scheduled formulations once in a year, in the month of April, on
the basis of the wholesale price index with respect to previous
calendar year and no prior approval of the Government in this regard
shall be required.
(3) Information about the revision, if carried out, shall be forwarded
to the Government in either electronic or physical form in Form-II
within a period of fifteen days of such revision and non-submission
of information under this sub-paragraph shall be construed as non
revision of maximum retail price (MRP) and the concerned
manufacturer shall be liable to deposit the amount charged over and
above the pre-revised maximum retail price (MRP), alongwith
interest thereon from the date of overcharging.
(4) In case of decline in wholesale price index, there shall be a
corresponding reduction in the maximum retail price and in case of
scheduled formulations produced or available in the market before
the date of notification of revised ceiling price, the manufacturers
shall ensure within a period of forty-five days of the date of such
notification that the maximum retail price (MRP) of such scheduled
formulation does not exceed the revised ceiling price (plus local
taxes as applicable) and information about the revision shall be sent
to the Government in either electronic or physical form in Form-II
within a period of fifteen days of such revision.
(5) Non-submission of information under the sub-paragraph (4) shall
be construed as non reduction in maximum retail price (MRP) and
the concerned manufacturer shall be liable to deposit the amount
charged over and above the maximum retail price revised based on
decline in wholesale price index, alongwith interest thereon as
overcharged amount from the date of overcharging.
Previous and next
Questions people ask
Is rule 16 of Drugs (Prices Control) Order, 2013 still in force?
No repeal of Drugs (Prices Control) Order, 2013 is recorded.